First Time Loading...

Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 66.75 USD 2.03%
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

GILD Price Targets Summary
Gilead Sciences Inc

Wall Street analysts forecast GILD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GILD is 86.54 USD with a low forecast of 69.69 USD and a high forecast of 127.05 USD.

GILD Lowest Forecast
Wall Street Target
69.69 USD
4% Upside
GILD Average Forecast
Wall Street Target
86.54 USD
30% Upside
GILD Highest Forecast
Wall Street Target
127.05 USD
90% Upside
Lowest
Price Target
69.69 USD
4% Upside
Average
Price Target
86.54 USD
30% Upside
Highest
Price Target
127.05 USD
90% Upside

GILD Last Price Targets
Gilead Sciences Inc

The latest public price target was made on Apr 24, 2024 by Morten Herholdt from HSBC , who expects GILD stock to rise by 3% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Morten Herholdt
HSBC
69 USD
Upside 3%
5 days ago
Apr 24, 2024
HSBC Upgrades Gilead Sciences (GILD) to Hold
StreetInsider
Brian Abrahams
RBC Capital
76 USD
Upside 14%
2 months ago
Feb 14, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Brian Abrahams
RBC Capital
84 USD
Upside 26%
7 months ago
Sep 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
Geoff Meacham
Bank of America Securities
95 USD
Upside 42%
7 months ago
Sep 8, 2023
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Benzinga
Unknown Analyst
Piper Sandler
112 USD
Upside 68%
1 year ago
Feb 3, 2023
Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $112
Benzinga
Unknown Analyst
Leerink Partners
91 USD
Upside 36%
1 year ago
Feb 3, 2023
SVB Leerink Maintains Market Perform on Gilead Sciences, Raises Price Target to $91
Benzinga
Show More Price Targets
Show Less Price Targets
Morten Herholdt
HSBC
Price Target 69 USD
Upside/Downside 3%
View Source
Brian Abrahams
RBC Capital
Price Target 76 USD
Upside/Downside 14%
View Source
Brian Abrahams
RBC Capital
Price Target 84 USD
Upside/Downside 26%
View Source
Geoff Meacham
Bank of America Securities
Price Target 95 USD
Upside/Downside 42%
View Source
Unknown Analyst
Piper Sandler
Price Target 112 USD
Upside/Downside 68%
View Source
Unknown Analyst
Leerink Partners
Price Target 91 USD
Upside/Downside 36%
View Source
Show More Price Targets
Show Less Price Targets
Gilead Sciences Inc Competitors:
Price Targets
ALERS
Eurobio Scientific SA
106% Upside
B
BAVA
Bavarian Nordic A/S
88% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
PYC
PYC Therapeutics Ltd
278% Upside
ALERS
Eurobio Scientific SA
106% Upside
B
BAVA
Bavarian Nordic A/S
88% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
PYC
PYC Therapeutics Ltd
278% Upside
PROB
Probi AB
55% Upside
IONS
Ionis Pharmaceuticals Inc
34% Upside
E
1952
Everest Medicines Ltd
7% Upside
1530
3SBio Inc
24% Upside

Revenue
Forecast

Revenue Estimate
Gilead Sciences Inc

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's revenue is -2%. The projected CAGR for the next 3 years is 3%.

-2%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Gilead Sciences Inc

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's operating income is -10%. The projected CAGR for the next 3 years is 11%.

-10%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-18%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Gilead Sciences Inc

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's net income is -14%. The projected CAGR for the next 3 years is 20%.

-14%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-40%
Average Miss
What are analyst estimates?

See Also

Summary
GILD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GILD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GILD stock valuation using valuation multiples.
Wall Street Estimates
GILD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GILD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GILD's stock price target?
Price Target
86.54 USD

According to Wall Street analysts, the average 1-year price target for GILD is 86.54 USD with a low forecast of 69.69 USD and a high forecast of 127.05 USD.

What is Gilead Sciences Inc's Revenue forecast?
Projected CAGR
3%

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's revenue is -2%. The projected CAGR for the next 3 years is 3%.

What is Gilead Sciences Inc's Operating Income forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's operating income is -10%. The projected CAGR for the next 3 years is 11%.

What is Gilead Sciences Inc's Net Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Gilead Sciences Inc's net income is -14%. The projected CAGR for the next 3 years is 20%.

ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.